Altimate Health, Massachusetts General Hospital Sign Agreement to Advance Precision Psychiatry
Tuesday, April 13, 2020
Altimate Health Corporation and Massachusetts General Hospital announced that they have signed a collaboration agreement for joint research, development, and commercialization in the emerging field of precision psychiatry. This is expected to lead to groundbreaking advances in the treatment of conditions including depression, substance use disorders, and serious mental illness including schizophrenia and bipolar disorder.
Dr. Maurizio Fava, Chief of Psychiatry at Massachusetts General Hospital (MGH), and a member of the scientific advisory board of Altimate, commented that “We have an opportunity to lead the development of ‘precision psychiatry’, which can account for individual differences in biology, environment and lifestyle, so we can develop more targeted and effective approaches to prevention, diagnosis, and treatment.”
“This collaboration allows us to accelerate the pace and impact of data-driven precision medicine to improve the health and well-being of people with behavioral health and psychiatric disorders”, according to Paul Pyzowski, CEO of Altimate.
According to Dr. Wasim Malik, Managing Director of Iaso Ventures, and an Altimate board member and co-founder, “The recent pandemic has brought much needed attention to the prevalence of mental illness. Digital health solutions are critical for physicians, insurers, and pharmaceutical companies to be able to address this ongoing public health crisis.”
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of “America’s Best Hospitals.”
Altimate Health is a Boston-based company founded to improve outcomes in people with behavioral health and psychiatric conditions through the innovative use of healthcare data, machine learning and artificial intelligence. The founding team includes executives with established track records in pharma, medtech, healthcare, and computer science.
Altimate Publishes on Preventing Serious Adverse Events for Patients with Opioid Use Disorder
Monday, August 17, 2020
Our new paper on predictive analytics in opioid use disorders is available! We have developed a method to predict relapse in a time window when a clinical intervention can be made. As far as we know this is the first quantitative method using only clinical data to predict imminent, patient-specific relapse, during an outpatient visit and when a clinical intervention can be made.
The full paper can be accessed HERE.
Machine Learning Applied to Clinical Laboratory Data Predicts Patient-Specific, Near-Term Relapse in Patients in Medication for Opioid Use Disorder Treatment
We have developed a data-driven, algorithmic method for identifying patients in an out- patient buprenorphine program at high risk for relapse in the following seven days. This method uses data already available in clinical laboratory data, can be made available in a timely matter, and is easily understandable and actionable by clinicians. Use of this method could significantly reduce the rate of relapse in addiction treatment programs by targeting interventions at those patients most at risk for near term relapse.